

Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

pSIH1-puro-control shRNA

RRID:Addgene_26597

Type: Plasmid

Proper Citation

RRID:Addgene_26597

Plasmid Information

URL: <http://www.addgene.org/26597>

Proper Citation: RRID:Addgene_26597

Insert Name: control shRNA

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:20197401](#)

Vector Backbone Description: Backbone Marker: System Biosciences; Backbone Size: 7200; Vector Backbone: pSIH1-H1-puro; Vector Types: Lentiviral, RNAi; Bacterial Resistance: Ampicillin

Comments: Control shRNA:
AATAGCGACTAAACACATCAATTCAAGAGATTGATGTGTTTAGTCGCTATTTTTTTT

Plasmid Name: pSIH1-puro-control shRNA

Record Creation Time: 20220422T222119+0000

Record Last Update: 20260902T045142+0000

Ratings and Alerts

No rating or validation information has been found for pSIH1-puro-control shRNA.

No alerts have been found for pSIH1-puro-control shRNA.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gao W, et al. (2024) Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma. *EBioMedicine*, 105, 105177.

Yanagimura N, et al. (2022) STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. *NPJ precision oncology*, 6(1), 11.

Zhang S, et al. (2022) MAFB promotes the malignant phenotypes by IGFBP6 in esophageal squamous cell carcinomas. *Experimental cell research*, 416(1), 113158.

Zhu X, et al. (2022) The Deubiquitinase USP39 Promotes Esophageal Squamous Cell Carcinoma Malignancy as a Splicing Factor. *Genes*, 13(5).

Wang Z, et al. (2022) Identification of a Metastasis-Related Protein IFI16 in Esophageal Cancer using a Proteomic Approach. *Journal of Cancer*, 13(5), 1630.

Nan Y, et al. (2022) DLGAP1-AS2-Mediated Phosphatidic Acid Synthesis Activates YAP Signaling and Confers Chemoresistance in Squamous Cell Carcinoma. *Cancer research*, 82(16), 2887.

Wright G, et al. (2021) Activated STAT3 Is a Novel Regulator of the XRCC1 Promoter and Selectively Increases XRCC1 Protein Levels in Triple Negative Breast Cancer. *International journal of molecular sciences*, 22(11).

Padder RA, et al. (2020) DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer. *Frontiers in oncology*, 10, 592130.

Oner E, et al. (2020) A promising approach to develop nanostructured lipid carriers from solid lipid nanoparticles: preparation, characterization, cytotoxicity and nucleic acid binding ability. *Pharmaceutical development and technology*, 25(8), 936.

Zhang J, et al. (2020) SERPINE2 promotes esophageal squamous cell carcinoma metastasis by activating BMP4. *Cancer letters*, 469, 390.

Luo Q, et al. (2020) TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. *Cell reports*, 30(1), 98.

Luo Q, et al. (2018) ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2. *Cancer letters*, 427, 9.

Yi L, et al. (2018) A Synthetic Disaccharide Derivative of Diphyllin, TAARD, Activates Human Natural Killer Cells to Secrete Interferon-Gamma via Toll-Like Receptor-Mediated NF- κ B and STAT3 Signaling Pathways. *Frontiers in immunology*, 9, 1509.

Nagathihalli NS, et al. (2015) Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. *Gastroenterology*, 149(7), 1932.

Agarwal S, et al. (2015) G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation. *Cancer research*, 75(12), 2566.

Shanker V, et al. (2013) Protein phosphatase 2A impairs IFN γ -induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation. *Journal of viral hepatitis*, 20(9), 612.

Lupberger J, et al. (2013) Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. *Hepatology (Baltimore, Md.)*, 58(4), 1225.

Canino C, et al. (2012) SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. *Oncogene*, 31(26), 3148.